Year: 2021

Posted on

W. L. Gore & Associates améliore le portefeuille d’endoprothèses GORE® VIABAHN® avec la pose d’un profil plus bas

Les améliorations apportées aux dispositifs de grand diamètre comprennent l’accessibilité par des gaines plus petites tout en permettant une meilleure visualisation grâce à l’ajout de marqueurs radio-opaques

25 ans d’innovation continue

PUTZBRUNN, Allemagne, 22 septembre 2021 /PRNewswire/ — Dans le cadre de ses efforts pour améliorer continuellement les solutions médicales pour les patients souffrant de maladies vasculaires complexes, W. L. Gore & Associates, Inc. (Gore) a annoncé le lancement dans la région EMEA de l’endoprothèse GORE® VIABAHN® à profil plus bas et à grand diamètre avec surface bioactive PROPATEN. Les améliorations apportées à ce dispositif s’appuient sur une endoprothèse leader sur le marché, qui est devenue un outil important pour le traitement des maladies vasculaires complexes. La conception innovante du dispositif VIABAHN® réduit le profil de pose des grandes endoprothèses de 9 à 13 mm de diamètre jusqu’à 3 CH, ce qui permet de les poser dans des gaines plus petites. Des gaines d’introduction plus petites ont permis de réduire le risque de complications liées à l’accès vasculaire chez certaines populations de patients.1 En outre, de nouveaux marqueurs radio-opaques, désormais présents sur les configurations de dispositifs de plus grand diamètre, améliorent la visualisation sous fluoroscopie, facilitant le positionnement et la pose du dispositif, ainsi qu’un placement précis et prévisible. « Outre les marqueurs radio-opaques qui facilitent le positionnement et le déploiement, le nouveau profil plus bas permet d’utiliser une gaine plus petite, ce qui réduit potentiellement le risque de dommages au niveau du site d’accès », a déclaré Manuel Alonso, docteur en médecine, chirurgien vasculaire, Oviedo, Espagne. « Associée à la traçabilité et à la flexibilité, cette nouvelle offre de profil plus bas deviendra très utile dans ma pratique pour traiter les patients complexes dans tous les états pathologiques. »

GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface

« L’histoire de l’endoprothèse GORE® VIABAHN® est l’histoire d’une collaboration entre médecins pour quatre indications centrées sur le patient et d’une performance prouvée à maintes reprises », a déclaré Benjamin Beckstead, responsable de la catégorie vasculaire chez Gore.

Depuis son lancement dans l’UE en 1996, le dispositif a évolué grâce à de nombreuses améliorations et a pris en charge des centaines de milliers de patients dans le monde entier. Actuellement, le dispositif VIABAHN® est utilisé dans de nombreuses indications cliniques telles que les lésions de l’artère fémorale superficielle (AFS), les lésions iliaques, la resténose intra-stent des lésions de l’AFS et les lésions du circuit d’accès artério-veineux (AV).*

Pour plus d’informations, rendez-vous sur le site https://www.goremedical.com/eu/products/viabahn

* Pour obtenir des indications complètes et d’autres informations importantes sur la sécurité des produits commerciaux Gore mentionnés dans le présent document, reportez-vous aux instructions d’utilisation.

1. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC : Cardiovascular Interventions 2008;1(3):317-326.

W. L. Gore & Associates Logo

Gore conçoit des dispositifs médicaux qui traitent toute une série de maladies cardiovasculaires et d’autres problèmes de santé. Avec plus de 50 millions de dispositifs médicaux implantés pendant plus de 45 ans, Gore s’appuie sur sa réputation pour améliorer le pronostic des patients à travers la recherche, la formation et la démarche qualité. L’efficacité des produits, la facilité d’utilisation et la qualité du service permettent aux médecins, aux hôpitaux et aux assureurs de réaliser des économies significatives. Gore est au service des cliniciens et grâce à cette collaboration, nous améliorons des vies.

À propos de Gore

W. L. Gore & Associates est une entreprise internationale spécialisée dans la science des matériaux et dont l’objectif est l’amélioration du secteur et des conditions de vie. Depuis 1958, Gore répond à des défis techniques complexes dans des environnements exigeants – de l’espace aux plus hauts sommets du monde en passant par le fonctionnement interne du corps humain. Avec plus de 11 000 associés et une forte culture axée sur le travail en équipe, Gore génère un chiffre d’affaires annuel de $3,8 milliards de dollars.

gore.com

Les produits énumérés peuvent ne pas être disponibles sur tous les marchés.

GORE, together, improving life, PROPATEN et HELEX, et les modèles sont des marques déposées de W. L. Gore & Associates.

Photo – https://mma.prnewswire.com/media/1628622/GORE_VSX_LDPro_final_highres.jpg

Logo – https://mma.prnewswire.com/media/340166/W_L_Gore_and_Associates_Logo.jpg

Posted on

W. L. Gore & Associates Enhances GORE® VIABAHN® Endoprosthesis Portfolio With Lower Profile Delivery

Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers

25 years of continued innovation

PUTZBRUNN, Germany, Sept. 22, 2021 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the EMEA launch of the lower profile, large diameter GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface. The device enhancements build on a market-leading stent graft device, which has become an important tool for treating complex vascular disease. The innovative VIABAHN® Device design reduces the delivery profile for larger 9–13 mm diameter stent grafts by up to 3 Fr, enabling delivery through smaller sheaths. Smaller introducer sheaths have resulted in a lower risk of vascular access complications in select patient populations.1 Additionally, new radiopaque markers, now also on the larger diameter device configurations, enhance visualization under fluoroscopy, facilitating positioning and device delivery, as well as precise and predictable placement. “In addition to the radiopaque markers that facilitate positioning and deployment, the new lower profile enables use of a smaller sheath, potentially reducing the risk of damage at the access site,” said Manuel Alonso, M.D., Vascular Surgeon, Oviedo, Spain. “Combined with the trackability and flexibility this new lower profile offering will become very instrumental for treating complex patients across disease states in my practice.”

GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface

“The story of the GORE® VIABAHN® Endoprosthesis is a story of physician collaboration across four patient-centric indications and of proving performance over and over,” said Benjamin Beckstead, Gore Vascular Category Leader.

Since its EU launch in 1996, the device has evolved with numerous enhancements and supported hundreds of thousands of patients worldwide. Currently, the VIABAHN® Device is used in various clinical indications such as in superficial femoral artery (SFA) lesions, iliac lesions, in-stent restenosis of SFA lesions and AV Access circuit lesions.*

For more information, visit https://www.goremedical.com/eu/products/viabahn

* For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).

1. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. JACC: Cardiovascular Interventions 2008;1(3):317-326.

W. L. Gore & Associates Logo

Gore engineers medical devices that treat a range of cardiovascular and other health conditions. With more than 50 million medical devices implanted over the course of more than 45 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives.

About Gore

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world’s highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion.

gore.com

Products listed may not be available in all markets.

GORE, Together, improving life, PROPATEN, VIABAHN and designs are trademarks of W. L. Gore & Associates.

Photo – https://mma.prnewswire.com/media/1628622/GORE_VSX_LDPro_final_highres.jpg

Logo – https://mma.prnewswire.com/media/340166/W_L_Gore_and_Associates_Logo.jpg

Posted on

Ten passengers feared dead in lake Victoria after boat capsizes

NAIROBI, Sept 22 (NNN-KBC) — Two passengers were confirmed dead, while eight others are still missing after a boat they were sailing capsized in Lake Victoria.

Six people were rescued during the incident near Pier Beach within Homa-Bay town when travelling to Ndhuru beach in Mbita Sub County Tuesday evening.

The boat is said to have capsized 400 meters away from the beach due to suspected overloading.

According to Homa-Bay town Chief Joshua Ochogo, the two bodies include that of a woman and a one and half year old minor who were retrieved during the rescue mission by fishermen who responded to the passengers distress call.

Ochogo said the six passengers who were rescued were taken to Homa-Bay county Referral Hospital for treatment while the two bodies were moved to the mortuary at the same facility.

He called for calm saying a search mission for the eight other passengers is ongoing amid fears that they could have drowned.

Source: NAM NEWS NETWORK

Posted on

China’s COVID-19 vaccine arrives in Denmark for UN Peacekeeping personnel

COPENHAGEN, Sept 22 (NNN-Xinhua) — A consignment of China’s Sinopharm COVID-19 vaccines arrived in Copenhagen as the Chinese government’s donation for United Nations Peacekeeping personnels.

The delivery ceremony of the donation was held virtually last Friday and those vaccines are expected to be distributed to front-line personnel and close partners through the UN system as soon as possible.

The Chinese donation will be used in the African mission area on a priority basis, said Zhang Maoyu, deputy head of the China International Development Cooperation Agency, at the delivery ceremony.

China’s donation will enhance the UN capacity to respond to the epidemic and help peacekeepers better fulfill their duties and missions, according to Christian Francis Saunders, UN’s Assistant Secretary-General for Supply Chain Management.

Source: NAM NEWS NETWORK

Posted on

Brazil and Argentina tapped to make mRNA COVID-19 vaccines in Latin America

BRASILIA, Sept 22 (NNN-AGENCIES) — The Pan American Health Organization (PAHO) has selected two biomedical centres in Argentina and Brazil as regional hubs to develop and produce mRNA-based vaccines to fight COVID-19 in Latin America, the regional health agency said.

The idea is to tap existing manufacturing capacities to help transfer vaccine technology developed by Moderna in the United States to a region badly hit by the coronavirus and still without access to enough vaccines.

The Bio-Manguinhos Institute of Technology on Immunobiologicals at Fiocruz, Brazil’s premier biomedical lab, was picked for its history of vaccine manufacturing, and has already made “promising advances” developing mRNA vaccine technology, PAHO said.

Sinergium Biotech, a private sector biopharmaceutical company, was selected as the centre in Argentina and will partner with pharmaceutical lab mAbxience of the same group to develop and manufacture active vaccine ingredients.

The Americas branch of the World Health Organization said vaccine manufacture should benefit the entire region, with distribution funded by PAHO’s Revolving Fund.

A similar effort in Africa to develop COVID-19 vaccine production replicating Moderna’s shot has been slowed by talks with the US company, a WHO official said last week.

Moderna said in October it would not enforce patents related to its shot during the pandemic, raising hopes that other companies might be able to copy its vaccine and help boost global production.

In practice, though, it is hard to replicate a vaccine without the information on how it is made, and the WHO-backed tech transfer hub in South Africa has so far not reached a deal with the company.

The Americas region has borne the brunt of COVID-19 infections to date, with 87.6 million cases recorded and over 2.16 million lives lost. Yet vaccine distribution continues to be unequal, PAHO has said, with few countries in the region reaching the year-end 40 per cent vaccine target set by the WHO.

Source: NAM NEWS NETWORK